Metelitsa V I, Martsevich S Iu, Riabokon' O S, Strel'tsov A A
Ter Arkh. 1986;58(3):45-9.
Eighty patients with ischemic heart disease and stable angina pectoris of effort were examined for the efficacy of dinitrosorbilong (DNL), a new long-acting drug based on isosorbide dinitrate (ID). The anti-ischemic effect of DNL appraised with the aid of repeated exercise lasted about 8h, which was on the average 4 h longer as compared with the duration of the anti-ischemic effect of ID tablets. The regular intake of DNL favoured an appreciable decrease in the number of angina pectoris attacks making it possible to lower nitroglycerin consumption. DNL was well tolerated by the patients.
对80例缺血性心脏病且劳力性稳定型心绞痛患者进行了研究，以考察二硝基山梨醇酯（DNL）的疗效，DNL是一种基于硝酸异山梨酯（ID）的新型长效药物。借助重复运动评估，DNL的抗缺血作用持续约8小时，与ID片剂的抗缺血作用持续时间相比，平均长4小时。规律服用DNL有利于明显减少心绞痛发作次数，从而降低硝酸甘油的消耗量。患者对DNL耐受性良好。
